- Home
- Publications
- Publication Search
- Publication Details
Title
New Advances in Targeted Therapy of HER2-Negative Breast Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-04
DOI
10.3389/fonc.2022.828438
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies
- (2022) Eman A. Abd El-Meguid et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Isoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/β-Catenin
- (2021) Fu Peng et al. AMERICAN JOURNAL OF CHINESE MEDICINE
- Gut Microbiota in Tumor Microenvironment: A Critical Regulator in Cancer Initiation and Development as Potential Targets for Chinese Medicine
- (2021) Li Wang et al. AMERICAN JOURNAL OF CHINESE MEDICINE
- PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer
- (2021) Ting Hong et al. Redox Biology
- Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
- (2021) Jessica L. Christenson et al. MOLECULAR CANCER THERAPEUTICS
- Biochanin A from Chinese Medicine: An Isoflavone with Diverse Pharmacological Properties
- (2021) Jia Yan et al. AMERICAN JOURNAL OF CHINESE MEDICINE
- Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
- (2021) D.J. Slamon et al. ANNALS OF ONCOLOGY
- New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer
- (2021) Junsha An et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MicroRNAs in Epithelial–Mesenchymal Transition Process of Cancer: Potential Targets for Chemotherapy
- (2021) Fu Peng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Aiduqing formula suppresses breast cancer metastasis via inhibiting CXCL1-mediated autophagy
- (2021) Bowen Yang et al. PHYTOMEDICINE
- Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway
- (2021) Anli Yang et al. Cell Death & Disease
- Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes
- (2021) Carolina Mathias et al. Frontiers in Oncology
- Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
- (2021) Erin R. Scheidemann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It
- (2021) Jiayu Zou et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
- (2021) Abeer J. Al-Qasem et al. Cancers
- LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
- (2021) Mengxing Li et al. Communications Biology
- Evaluation of the PIK3 pathway in peripheral T‐cell lymphoma and NK/T‐cell lymphoma
- (2020) Dachuan Huang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
- (2020) Po‐Han Lin et al. CANCER SCIENCE
- Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements
- (2020) Vaishali Aggarwal et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Long non‑coding RNA profile revealed by microarray indicates that lncCUEDC1 serves a negative regulatory role in breast cancer stem cells
- (2020) Fengchun Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells
- (2020) Zhen Xu et al. PHARMACOLOGICAL RESEARCH
- Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
- (2020) Sima Lev BIOCHEMICAL SOCIETY TRANSACTIONS
- Engineering mesenchymal stem cells: a novel therapeutic approach in breast cancer
- (2020) Razieh Heidari et al. JOURNAL OF DRUG TARGETING
- NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
- (2020) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Therapeutic applications of PARP inhibitors in ovarian cancer
- (2020) Hongyu Xie et al. BIOMEDICINE & PHARMACOTHERAPY
- Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
- (2020) Terence C. S. Ho et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib ( LY2606368 ) in BRCA Wild‐Type , Advanced Triple‐Negative Breast Cancer
- (2020) Margaret E. Gatti‐Mays et al. ONCOLOGIST
- Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – A comprehensive review from chemotherapy to immunotherapy
- (2020) Parham Jabbarzadeh Kaboli et al. PHARMACOLOGICAL RESEARCH
- Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study
- (2020) Emily Heer et al. Lancet Global Health
- Clinical Impact of Breast Cancer Stem Cells in Metastatic Breast Cancer Patients
- (2020) M. A. Elbaiomy et al. Journal of Oncology
- ARe we there yet? Understanding androgen receptor signaling in breast cancer
- (2020) Anna R. Michmerhuizen et al. npj Breast Cancer
- Downregulation of cytokeratin 18 induces cellular partial EMT and stemness through increasing EpCAM expression in breast cancer
- (2020) Ruizan Shi et al. CELLULAR SIGNALLING
- Encapsulated human mesenchymal stem cells (eMSCs) as a novel anti-cancer agent targeting breast cancer stem cells: Development of 3D primed therapeutic MSCs
- (2019) Saurabh Mandal et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133
- (2019) Hongran Yin et al. MOLECULAR THERAPY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Umbilical cord–derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data
- (2019) MARTINA COLLICHIA et al. CYTOTHERAPY
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- The outcome of TGFβ antagonism in metastatic breast cancer models in vivo reflects a complex balance between tumor-suppressive and pro-progression activities of TGFβ
- (2019) Yuan Yang et al. CLINICAL CANCER RESEARCH
- EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers
- (2019) Lucyna Matusewicz et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- MicroRNAs, a Promising Target for Breast Cancer Stem Cells
- (2019) Plabon Kumar Das et al. Molecular Diagnosis & Therapy
- Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival
- (2019) K. Wimmer et al. ANNALS OF SURGICAL ONCOLOGY
- Lovastatin‐mediated MCF‐7 cancer cell death involves LKB1‐AMPK‐p38MAPK‐p53‐survivin signalling cascade
- (2019) Shiu‐Wen Huang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells
- (2019) Gamze Guney Eskiler JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- PI3K Inhibitors in Breast Cancer Therapy
- (2019) Haley Ellis et al. Current Oncology Reports
- Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
- (2018) Sarika Jain et al. BREAST CANCER RESEARCH AND TREATMENT
- PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey
- (2018) Panagiotis A. Konstantinopoulos et al. CLINICAL CANCER RESEARCH
- Relationship between morphological development and sex hormone receptor expression of mammary glands with age in male rats
- (2018) Yoko MIYAMOTO et al. EXPERIMENTAL ANIMALS
- Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival
- (2018) Andrew Baker et al. ONCOGENE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer stem cells (CSCs) in cancer progression and therapy
- (2018) Masoud Najafi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Enhancing chemosensitivity of breast cancer stem cells by down regulating SOX2 and ABCG2 using Wedelolactone-encapsulated nanoparticles
- (2018) Sreemanti Das et al. MOLECULAR CANCER THERAPEUTICS
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
- (2017) Nandini Dey et al. PHARMACOLOGY & THERAPEUTICS
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
- (2016) Angel Guerrero-Zotano et al. CANCER AND METASTASIS REVIEWS
- Targeted adjuvant therapy in breast cancer
- (2016) Dimitrios Zardavas et al. Expert Review of Anticancer Therapy
- Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer
- (2016) Nadine Tung et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer
- (2016) A E Witt et al. ONCOGENE
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress
- (2016) Yao Zhang et al. Oncotarget
- High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer
- (2016) Siker Kimbung et al. Oncotarget
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Discovery of novel nonpeptide allosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays
- (2015) Yutong Hu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a
- (2015) Adam R. Wolfe et al. BREAST CANCER RESEARCH AND TREATMENT
- Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis
- (2015) Wenzhe Si et al. CANCER CELL
- Targeted Therapy for Cancer in the Genomic Era
- (2015) Anosheh Afghahi et al. CANCER JOURNAL
- Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment
- (2015) T. VanArsdale et al. CLINICAL CANCER RESEARCH
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
- (2015) GEORGE MIHAI NITULESCU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- BRCA1 phosphorylation by Aurora-A in the regulation of G2to M transition.
- (2015) Mutsuko Ouchi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structural and Biophysical Characterization of the Interactions between Calmodulin and the Pleckstrin Homology Domain of Akt
- (2015) Constance Agamasu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Statin-Based Palliative Therapy for Hepatocellular Carcinoma
- (2015) Joni Yu-Hsuan Shao et al. MEDICINE
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo
- (2015) Nan Yao et al. TUMOR BIOLOGY
- Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors
- (2015) Fangbin Han et al. ACS Medicinal Chemistry Letters
- The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
- (2015) Marion Peyressatre et al. Cancers
- Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
- (2015) Yi Yu et al. PLoS One
- Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
- (2015) Nicole M. Davis et al. Oncotarget
- Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling
- (2015) Ilenia Segatto et al. Oncotarget
- PI3K/AKT signaling pathway and cancer: an updated review
- (2014) Miriam Martini et al. ANNALS OF MEDICINE
- Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer
- (2014) Jung Eun Choi et al. ANNALS OF SURGICAL ONCOLOGY
- Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
- (2014) M. A. Dickson CLINICAL CANCER RESEARCH
- Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer
- (2014) Xichun Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Fluvastatin Mediated Breast Cancer Cell Death: A Proteomic Approach to Identify Differentially Regulated Proteins in MDA-MB-231 Cells
- (2014) Anantha Koteswararao Kanugula et al. PLoS One
- Integrating Genomics and Proteomics Data to Predict Drug Effects Using Binary Linear Programming
- (2014) Zhiwei Ji et al. PLoS One
- Highlights of the Latest Advances in Research on CDK Inhibitors
- (2014) Jonas Cicenas et al. Cancers
- Kinase Drug Discovery – What’s Next in the Field?
- (2013) Philip Cohen et al. ACS Chemical Biology
- Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
- (2013) Emilia Mahoney et al. Autophagy
- A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia
- (2013) Jiewen Zhu et al. EMBO Molecular Medicine
- Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice
- (2013) Alessio Giubellino et al. ENDOCRINOLOGY
- ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
- (2013) Agnese Anna Abate et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Optimization of Non-ATP Competitive CDK/Cyclin Groove Inhibitors through REPLACE-Mediated Fragment Assembly
- (2013) Shu Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- The causes and consequences of genetic heterogeneity in cancer evolution
- (2013) Rebecca A. Burrell et al. NATURE
- Reduced Androgen Receptor Expression Accelerates the Onset of ERBB2 Induced Breast Tumors in Female Mice
- (2013) Myles C. Hodgson et al. PLoS One
- Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
- (2013) David Davidson et al. Frontiers in Pharmacology
- Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features
- (2012) Zhizhou Fang et al. ACS Chemical Biology
- Contrasting effects of sunitinib within in vivo models of metastasis
- (2012) Jonathan C. Welti et al. ANGIOGENESIS
- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K
- (2012) J. M. Munck et al. MOLECULAR CANCER THERAPEUTICS
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- The role of immunosuppression of mesenchymal stem cells in tissue repair and tumor growth
- (2012) Zhipeng Han et al. Cell and Bioscience
- Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
- (2011) Wenqing Qi et al. BIOCHEMICAL PHARMACOLOGY
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- (2011) Min Ni et al. CANCER CELL
- Peptides or Small Molecules? Different Approaches to Develop More Effective CDK Inhibitors
- (2011) D. Cirillo et al. CURRENT MEDICINAL CHEMISTRY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- CDC25 Phosphatase Inhibitors: An Update
- (2011) A. Lavecchia et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells
- (2011) Judy S. Su et al. NMR IN BIOMEDICINE
- Anticancer therapy with checkpoint inhibitors: what, where and when?
- (2011) Michelle D. Garrett et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors
- (2010) Richard M Eglen et al. Expert Opinion on Drug Discovery
- Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer
- (2010) Askmalm INTERNATIONAL JOURNAL OF ONCOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Aurora kinase inhibitors
- (2009) J.J.E.M. Kitzen et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Calmodulin modulates Akt activity in human breast cancer cell lines
- (2008) Christine M. Coticchia et al. BREAST CANCER RESEARCH AND TREATMENT
- Endostar Suppresses Invasion Through Downregulating the Expression of Matrix Metalloproteinase-2/9 in MDA-MB-435 Human Breast Cancer Cells
- (2008) Na Lu et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started